MedTrace Logo

Efficacy and Safety of Fufangdanshen Tablets in Mild to Moderate Vascular Dementia

NCT01761227 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2018-10-23

No results posted yet for this study

Summary

Purpose: The purpose of this study is to examine the efficacy and safety of Fufangdanshen Tablets in patients with mild to moderate vascular dementia (VaD).

Conditions

  • Vascular Dementia

Interventions

DRUG

Fufangdanshen Tablets

1 tablets contains contains tanshinoneⅡA 0.67mg , salvianolic acid B 8.2mg, Panax Notoginsenosides R1 0.53mg, ginsenoside Rb1 3.03mg, ginsenoside Rg1 2.73mg, 3 tablets per time, 3 times per day for 24 weeks

DRUG

Placebo

Placebo for 3 tablets per time, 3 times per day for 24 weeks

Sponsors & Collaborators

  • Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited

    collaborator INDUSTRY

  • Dongzhimen Hospital, Beijing

    lead OTHER

Principal Investigators

  • Jinzhou Tian, Ph.D, M.D · Dongzhimen Hospital, Beijing

  • Jing Shi, M.D · Dongzhimen Hospital, Beijing

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01761227 on ClinicalTrials.gov